ArticleThe oncologist2022

Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab.

Giulia Pasello et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.